Differential Diagnosis and Therapeutic Management of Schizoaffective Disorder

Joseph F. Goldberg, MD; Christoph U. Correll, MD; Henry A Nasrallah, MD
Credit Type
1.0
Credit Amount
1
Release Date
10/01/2010
Expiration Date
10/30/2011
Activity Type
Compendium

 

Jointly sponsored by Albert Einstein College of Medicine, Montefiore Medical Center, and Asante Communications, LLC.  This activity is supported by an educational grant from Janssen, Division of Ortho-McNeil Janssen Pharmaceuticals, Inc., administered by Ortho-McNeil-Janssen Scientific Affairs, LLC.

Current Psychiatry provided a critical peer-review of the scientific/medical content of this activity.

Activity Goal

The goal of this activity is to educate psychiatrists and other health care professionals on best practices in the assessment, diagnosis, treatment, and ongoing care of patients with schizoaffective disorder (SAD).

Intended Audience

This activity is intended for psychiatrists and other health care professionals interested in improving their knowledge base and skill sets in the individualized assessment and management of patients with schizoaffective disorder.

Statement of Need

Patients with SAD must satisfy the criteria for both schizophrenia and either a major depressive episode or a manic/mixed episode.3 The prevalence of SAD has been estimated at nearly 1% of the US population.3 Although first characterized nearly 80 years ago, the evidence base supporting differential diagnosis and therapeutic management is limited. Clinical studies have frequently evaluated heterogeneous patient populations. Consequently, much of the guidance for diagnostic and therapeutic management derives from studies of schizophrenia, a similar but nevertheless distinct disorder.7

Schizoaffective disorder remains difficult to define, monitor, and treat.  Long-term evaluation of patients with SAD, in particular, presents distinct challenges, not least because of its often evolving symptomatology.4 Diagnostic changes are not unusual and require tight clinical management. The paucity of peer-reviewed evidence specifically addressing this clinical construct confounds treatment, however. Recent scientific and clinical advances in our understanding of SAD risk factors, pathogenesis, and management highlight an important need among psychiatrists for peer-to-peer education.

Learners Gap

Patients with SAD meet criteria for schizophrenia, while also meeting criteria for major depressive disorder or mania, and will have periods of psychosis without mood disorder symptoms. SAD remains underdiagnosed in part because it is frequently confused with other psychiatric disorders with overlapping diagnostic criteria— chiefly schizophrenia, bipolar disorder, and major depressive disorder. Understanding the collaborative management of patients with SAD is an important educational imperative for psychiatrists and other health care professionals. Considerable gaps in level-1 evidence mirror the need for psychiatrists to exchange insights into this heterogeneous clinical construct and its clinical management.

Learning Objectives

At the conclusion of this program, participants will be better prepared to: 

  • Conduct initial and ongoing assessment of patients with schizoaffective disorder (SAD), identifying comorbidities, current and prior medical history, and treatment goals
  • Diagnose SAD, differentiating it from schizophrenia, bipolar disorder, and major depressive disorder
  • Design and implement an appropriate multimodal treatment plan tailored to the patient’s SAD subtype and medical comorbidities
  • Implement psychosocial and psychopharmacologic interventions shown to improve treatment outcomes in patients with SAD
  • Utilize psychosocial and pharmacologic strategies to improve treatment adherence among patients with SAD

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Albert Einstein College of Medicine and Montefiore Medical Center and Asante Communications, LLC. Albert Einstein College of Medicine is accredited by the ACCME to provide continuing medical education (CME) for physicians.

Credit Designation

Albert Einstein College of Medicine designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Conflict of Interest Statement

The Conflict of Interest Disclosure Policy of Albert Einstein College of Medicine requires that faculty participating in any CME activity disclose to the audience any relationship(s) with a pharmaceutical, product, or device company. Any presenters whose disclosed relationships prove to create a conflict of interest with regard to their contribution to the activity will not be permitted to present.

Albert Einstein College of Medicine also requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

Joseph F. Goldberg, MD: AstraZeneca (Speaker’s Bureau); Cephalon, Inc. (Consultant); Eli Lilly and Company (Speaker’s Bureau, Consultant); GlaxoSmithKline (Speaker’s Bureau); Janssen-Cilag (Lecture); Merck & Co., Inc. (Speaker’s Bureau); Pfizer Inc. (Speaker’s Bureau).

Henry A. Nasrallah, MD: AstraZeneca (Speaker’s Bureau, Consultant); Forest Pharmaceuticals (Grants/Research); Janssen (Speaker’s Bureau, Consultant, Grants/ Research); Merck & Co., Inc. (Speaker’s Bureau, Consultant); Novartis (Speaker’s Bureau, Consultant); Otsuka Pharmaceuticals (Grants/Research); Pfizer Inc.(Speaker’s Bureau, Consultant); Sepracor/Sunovion (Consultant); Shire Pharmaceuticals (Grants/Research).

Christoph U. Correll, MD: Consultant and/ or advisor to or has received honoraria from Actelion Pharmaceuticals; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Cephalon, Inc.; Eli Lilly and Company; GlaxoSmithKline; Hoffmann- La Roche; IntraCellular Therapeutics; Janssen; Lundbeck Inc.; Medicure; Otsuka Pharmaceuticals; Pfizer Inc.; Schering-Plough; Sepracor/Sunovion; Supernus Pharmaceuticals; Takeda; Vanda Pharmaceuticals Inc.

Christopher Ontiveros, PhD (Medical Writer): Has no conflict of interest(s) to report.

Albert Einstein College of Medicine and Montefiore Medical Center, Center for Continuing Medical Education (CCME) staff, and the staff of Asante Communications, LLC, have no conflicts of interest with commercial interests related directly or indirectly to this educational activity.

The staff at Albert Einstein College of Medicine has no disclosures to report other than the following:

Steven Jay Feld, or a member of his household, owns securities in Bioheart, Inc.; Chelsea Therapeutics, Inc.; and Pharmacopeia, Inc.

Copyright Information

Copyright ©2010 Albert Einstein College of Medicine and Montefiore Medical Center and Asante Communications, LLC. All rights reserved. No part of this monograph may be used or reproduced in any manner whatsoever without written permission except in the case of brief quotations embodied in articles or reviews.

References

1. Azorin JM, Kaladjian A, Fakra E. Current issues on schizoaffective disorder. Encephale. 2005;31(3):359-365.
2. Kent S, Fogarty M, Yellowlees P. Heavy utilization of inpatient and outpatient services in a public mental health service. Psychiatric services (Washington, D.C.). 1995;46(12):1254-1257.
3. Diagnostic and statistical manual of mental disorders, 4th ed, text rev. Washington, DC: American Psychiatric Association; 2000.
4. Kempf L, Hussain N, Potash JB. Mood disorder with psychotic features, schizoaffective disorder, and schizophrenia with mood features: trouble at the borders. Int Rev Psychiatry. 2005;17(1):9-19. 
5. The ICD-10 classification of mental and behavioural disorders. Diagnostic criteria for research. Geneva: World Health Organization; 1993. 
6. Perala J, Suvisaari J, Saarni SI, et al. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch Gen Psychiatry. 2007;64(1):19-28. 
7. Tsuang MT. Morbidity risks of schizophrenia and affective disorders among first-degree relatives of patients with schizoaffective disorders. Br J Psychiatry. 1991;158(2):165-170.
8. Maj M, Pirozzi R, Formicola AM, et al. Reliability and validity of the DSMIV diagnostic category of schizoaffective disorder: preliminary data. J Affect Disord. 2000;57(1-3):95-98.
9. Levitt JJ, Tsuang MT. The heterogeneity of schizoaffective disorder: implications for treatment. Am J Psychiatry. 1988;145(8):926-936.
10. Tsuang D, Coryell W. An 8-year follow-up of patients with DSM-III-R psychotic depression, schizoaffective disorder, and schizophrenia. Am J Psychiatry. 1993;150(8):1182-1188.
11. Evans JD, Heaton RK, Paulsen JS, et al. Schizoaffective disorder: a form of schizophrenia or affective disorder? J Clin Psychiatry. 1999;60(12):874-882.
12. Akiskal HS. The prevalent clinical spectrum of bipolar disorders: beyond DSM-IV. J Clin Psychopharmacol. 1996;16(2 Suppl 1):4S-14S.
13. Kendler KS, McGuire M, Gruenberg AM, et al. Examining the validity of DSM-III-R schizoaffective disorder and its putative subtypes in the Roscommon Family Study. Am J Psychiatry. 1995;152(5):755-764. 
14. Crow TJ. Nature of the genetic contribution to psychotic illness—a continuum viewpoint. Acta Psychiatr Scand. 1990;81(5):401-408. 
15. Cheniaux E, Landeira-Fernandez J, Lessa Telles L, et al. Does schizoaffective disorder really exist? A systematic review of the studies that compared schizoaffective disorder with schizophrenia or mood disorders. J Affect Disord. 2008;106(3):209-217.
16. Mansour HA, Talkowski ME, Wood J, et al. Association study of 21 circadian genes with bipolar I disorder, schizoaffective disorder, and schizophrenia.  Bipolar Disord. 2009;11(7):701-710. 
17. Potash JB. Carving chaos: genetics and the classification of mood and psychotic syndromes. Harv Rev Psychiatry. 2006;14(2):47-63. 
18. Gruber O, Gruber E, Falkai P. Articulatory rehearsal in verbal working memory: a possible neurocognitive endophenotype that differentiates between schizophrenia and schizoaffective disorder. Neurosci Lett. 2006;405(1-2):19.
19. Stip E, Sepehry AA, Prouteau A, et al. Cognitive discernible factors between schizophrenia and schizoaffective disorder. Brain Cogn. 2005;59(3):292-295.
20. Laursen TM, Labouriau R, Licht RW, et al. Family history of psychiatric illness as a risk factor for schizoaffective disorder: a Danish register-based cohort study. Arch Gen Psychiatry. 2005;62(8):841-848.
21. Golubovic B, Misic-Pavkov G, Gajic Z, et al. Evaluation of quality of life for patients with schizophrenic and schizoaffective disorders related to the use of antipsychotic therapy. Med Arh. 2010;64(1):37-40. 
22. Hasson-Ohayon I, Kravetz S, Meir T, et al. Insight into severe mental illness, hope, and quality of life of persons with schizophrenia and schizoaffective disorders. Psychiatry Res. 2009;167(3):231-238.
23. Basu R, Brar JS, Chengappa KN, et al. The prevalence of the metabolic syndrome in patients with schizoaffective disorder—bipolar subtype. Bipolar Disord. 2004;6(4):314-318.
24. Olfson M, Marcus SC, Wan GJ. Treatment patterns for schizoaffective disorder and schizophrenia among Medicaid patients. Psychiatric services (Washington, D.C.). 2009;60(2):210-216.
25. Cosoff SJ, Hafner RJ. The prevalence of comorbid anxiety in schizophrenia, schizoaffective disorder and bipolar disorder. Aust N Z J Psychiatry. 1998; 32(1):67-72. 
26. Maayan L, Correll CU. Management of antipsychotic-related weight gain. Ex-pert Rev Neurother. 2010;10(7):1175-1200. 
27. Schwartz JE, Fennig S, Tanenberg-Karant M, et al. Congruence of diagnoses 2 years after a first-admission diagnosis of psychosis. Arch Gen Psychiatry. 2000; 57(6):593-600.
28. Salvatore P, Baldessarini RJ, Tohen M, et al. McLean-Harvard International First-Episode Project: two-year stability of DSM-IV diagnoses in 500 first-episode psychotic disorder patients. J Clin Psychiatry. 2009;70(4):458-466. 
29. Nardi AE, Nascimento I, Freire RC, et al. Demographic and clinical features of schizoaffective (schizobipolar) disorder—a 5-year retrospective study. Support for a bipolar spectrum disorder. J Affect Disord. 2005;89(1-3):201-206.
30. Levinson DF, Umapathy C, Musthaq M. Treatment of schizoaffective disorder and schizophrenia with mood symptoms. Am J Psychiatry. 1999;156(8):1138-1148.
31. Canuso CM, Lindenmayer JP, Kosik-Gonzalez C, et al. A randomized, double-blind, placebo-controlled study of 2 dose ranges of paliperidone extended-release in the treatment of subjects with schizoaffective disorder. J Clin Psychiatry. 2010;71(5):587-598. 
32. Rabinowitz J, Levine S, Martinez G. Concordance between measures of functioning, symptoms, and change: examining the GAF, CGI-S, CGI-C, and PANSS. J Clin Psychopharmacol. 2010;30(4):478-480.
33. Canuso CM, Schooler N, Kosik-Gonzalez C, et al. A randomized, double-blind, placebo-controlled study of flexible-dose paliperidone ER in the treatment of patients with schizoaffective disorder. Paper presented at: International Congress on Schizophrenia Research; Mar 28-Apr 1, 2009; San Diego, CA.
34. Canuso CM, Lindenmayer JP, Kosik-Gonzalez C, et al. A randomized, double-blind, placebo-controlled study of paliperidone ER in the treatment of subjects with schizoaffective disorder [poster]. Paper presented at: U.S. Psychiatric and Mental Health Congress; Oct 30-Nov 2, 2008; San Diego, CA.
35. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-276.
36. Keck PE, Jr., Reeves KR, Harrigan EP. Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double- blind, placebo-controlled, multicenter studies. J Clin Psychopharmacol. 2001;21(1):27-35. 
37. Tohen M, Zhang F, Keck PE, et al. Olanzapine versus haloperidol in schizoaffective disorder, bipolar type. J Affect Disord. 2001;67(1-3):133-140. 
38. Tran PV, Tollefson GD, Sanger TM, et al. Olanzapine versus haloperidol in the treatment of schizoaffective disorder. Acute and long-term therapy. Br J Psychiatry. 1999;174:15-22.
39. Janicak PG, Keck PE, Jr., Davis JM, et al. A double-blind, randomized, prospective evaluation of the efficacy and safety of risperidone versus haloperidol in the treatment of schizoaffective disorder. J Clin Psychopharmacol. 2001; 21(4):360-368.
40. Jager M, Becker T, Weinmann S, et al. Treatment of schizoaffective disorder—a challenge for evidence-based psychiatry. Acta Psychiatr Scand. 2009;121(1):22-32.
41. Perlis RH, Welge JA, Vornik LA, et al. Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials. J Clin Psychiatry. 2006;67(4):509-516.
42. Bowden CL, Grunze H, Mullen J, et al. A randomized, double-blind, placebocontrolled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry. 2005;66(1):111-121. 
43. Hirschfeld RM, Keck PE, Jr., Kramer M, et al. Rapid antimanic effect of risperi-done monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. Am J Psychiatry. 2004;161(6):1057-1065.
44. McElroy SL, Keck PE, Jr., Strakowski SM. An overview of the treatment of schizoaffective disorder. J Clin Psychiatry.1999;60 (Suppl 5):16-21; discussion 22.
45. Mensink GJ, Slooff CJ. Novel antipsychotics in bipolar and schizoaffective mania. Acta Psychiatr Scand. 2004;109(6):405-419.
46. Mattes JA, Nayak D. Lithium versus fluphenazine for prophylaxis in mainly schizophrenic schizo-affectives. Biol Psychiatry. 1984;19(3):445-449.
47. Greil W, Ludwig-Mayerhofer W, Erazo N, et al. Lithium vs carbamazepine in the maintenance treatment of schizoaffective disorder: a randomised study. Eur Arch Psychiatry Clin Neurosci. 1997;247(1):42-50. 
48. Velligan DI, Weiden PJ, Sajatovic M, et al. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry. 2009;70(Suppl 4):1-46; quiz 47-48.
49. Valenstein M, Copeland LA, Blow FC, et al. Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Med Care. 2002;40(8):630-639.
50. Valenstein M, Blow FC, Copeland LA, et al. Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophr Bull. 2004;30(2):255-264. 
51. Peuskens J, Olivares JM, Pecenak J, et al. Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries. Curr Med Res Opin. 2010;26(3):501-509. 
52. Diaz E, Neuse E, Sullivan MC, et al. Adherence to conventional and atypical antipsychotics after hospital discharge. J Clin Psychiatry. 2004;65(3):354-360. 
53. Chengappa KN, Parepally H, Brar JS, et al. A random-assignment, double-blind, clinical trial of once- vs twice-daily administration of quetiapine fumarate in patients with schizophrenia or schizoaffective disorder: a pilot study. Can J Psychiatry. 2003;48(3):187-194. 
54. Gelenberg AJ. Using assessment tools to screen for, diagnose, and treat major depressive disorder in clinical practice. J Clin Psychiatry. 2010;71;(Suppl E1):e01. 
55. Young RC, Biggs, JT, Ziegber VE, et al. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429-435. 
56. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep. 1962;10:799-812. 
57. Sharp LK, Lipsky MS. Screening for depression across the lifespan: a review of measures for use in primary care settings. Am Fam Physician. 2002;66(6):1001-1008.

Begin Activity